Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oskar Vilhelmsson Timmermand

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|November 25, 2023
Imaging the Tumor Antioxidant Response with [<sup>18</sup>F]FSPG PETOskar Vilhelmsson Timmermand, Timothy H Witney
Anticancer Research|January 2, 2016
Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma RaysJörgen Elgqvist, Oskar Vilhelmsson Timmermand, Erik Larsson, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 22, 2023
Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft modelOskar Vilhelmsson Timmermand, Marcella Safi, Bo Holmqvist, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2023
Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical TherapyEmma Mellhammar, Magnus Dahlbom, Oskar Vilhelmsson-Timmermand, et al.
EJNMMI Physics|July 19, 2022
Small-scale dosimetry for alpha particle <sup>241</sup>Am source cell irradiation and estimation of γ-H2AX foci distribution in prostate cancer cell line PC3Emma Mellhammar, Magnus Dahlbom, Oskar Vilhelmsson-Timmermand, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 7, 2015
Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapyOskar Vilhelmsson Timmermand, Thuy A Tran, Sven-Erik Strand, et al.
Biochemical and Biophysical Research Communications|July 5, 2024
Investigating Ras homolog gene family member C (RhoC) and Ki67 expression following external beam radiation therapy show increased RhoC expression in relapsing prostate cancer xenograftsAmanda Kristiansson, Crister Ceberg, Anders Bjartell, et al.
Seminars in Nuclear Medicine|February 22, 2016
Radioimmunotherapy for Prostate Cancer--Current Status and Future PossibilitiesSusan Evans-Axelsson, Oskar Vilhelmsson Timmermand, Anders Bjartell, et al.
EJNMMI Research|March 25, 2026
Fractionation gives therapeutic benefit in animal model of [<sup>177</sup>Lu]Lu-PSMA-617 therapy of prostate cancerOskar Vilhelmsson Timmermand, Axel Östholm, Wahed Zedan, et al.
Antioxidants (Basel, Switzerland)|August 27, 2021
Kidney Protection with the Radical Scavenger α<sub>1</sub>-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand TherapyAmanda Kristiansson, Anders Örbom, Oskar Vilhelmsson Timmermand, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Methods in Molecular Biology (Clifton, N.J.)|November 25, 2023
Imaging the Tumor Antioxidant Response with [<sup>18</sup>F]FSPG PETOskar Vilhelmsson Timmermand, Timothy H Witney
Anticancer Research|January 2, 2016
Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma RaysJörgen Elgqvist, Oskar Vilhelmsson Timmermand, Erik Larsson, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 22, 2023
Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft modelOskar Vilhelmsson Timmermand, Marcella Safi, Bo Holmqvist, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2023
Tumor Control Probability and Small-Scale Monte Carlo Dosimetry: Effects of Heterogenous Intratumoral Activity Distribution in Radiopharmaceutical TherapyEmma Mellhammar, Magnus Dahlbom, Oskar Vilhelmsson-Timmermand, et al.
EJNMMI Physics|July 19, 2022
Small-scale dosimetry for alpha particle <sup>241</sup>Am source cell irradiation and estimation of γ-H2AX foci distribution in prostate cancer cell line PC3Emma Mellhammar, Magnus Dahlbom, Oskar Vilhelmsson-Timmermand, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 7, 2015
Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapyOskar Vilhelmsson Timmermand, Thuy A Tran, Sven-Erik Strand, et al.
Biochemical and Biophysical Research Communications|July 5, 2024
Investigating Ras homolog gene family member C (RhoC) and Ki67 expression following external beam radiation therapy show increased RhoC expression in relapsing prostate cancer xenograftsAmanda Kristiansson, Crister Ceberg, Anders Bjartell, et al.
Seminars in Nuclear Medicine|February 22, 2016
Radioimmunotherapy for Prostate Cancer--Current Status and Future PossibilitiesSusan Evans-Axelsson, Oskar Vilhelmsson Timmermand, Anders Bjartell, et al.
EJNMMI Research|March 25, 2026
Fractionation gives therapeutic benefit in animal model of [<sup>177</sup>Lu]Lu-PSMA-617 therapy of prostate cancerOskar Vilhelmsson Timmermand, Axel Östholm, Wahed Zedan, et al.
Antioxidants (Basel, Switzerland)|August 27, 2021
Kidney Protection with the Radical Scavenger α<sub>1</sub>-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand TherapyAmanda Kristiansson, Anders Örbom, Oskar Vilhelmsson Timmermand, et al.
Pageof 3